Remicade and Eye penetration - a phase IV clinical study of FDA data


Eye penetration is reported only by a few people who take Remicade.

The phase IV clinical study analyzes which people take Remicade and have Eye penetration. It is created by eHealthMe based on reports of 201,081 people who have side effects while taking Remicade from the FDA, and is updated regularly.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Jan, 08, 2023

201,081 people reported to have side effects when taking Remicade.
Among them, 4 people (0.0%) have Eye penetration.

What is Remicade?

Remicade has active ingredients of infliximab. It is often used in crohn's disease. eHealthMe is studying from 202,410 Remicade users for its effectiveness, alternative drugs and more.

What is Eye penetration?

Eye penetration is found to be associated with 126 drugs and 90 conditions by eHealthMe.

Number of Remicade and Eye penetration reports submitted per year:

Could Remicade cause Eye penetration?

Gender of people who have Eye penetration when taking Remicade *:

  • female: 100 %
  • male: 0.0 %

Age of people who have Eye penetration when taking Remicade *:

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 0.0 %
  • 40-49: 25 %
  • 50-59: 25 %
  • 60+: 50 %

Common drugs people take besides Remicade *:

  1. Methotrexate: 2 people, 50.00%
  2. Tolbutamide: 1 person, 25.00%
  3. Prednisone: 1 person, 25.00%
  4. Pentasa: 1 person, 25.00%
  5. Metformin: 1 person, 25.00%
  6. Levothyroxine Sodium: 1 person, 25.00%
  7. Fosamax: 1 person, 25.00%
  8. Folic Acid: 1 person, 25.00%
  9. Cyclophosphamide: 1 person, 25.00%
  10. Azathioprine: 1 person, 25.00%

Common side effects people have besides Eye penetration *:

  1. Uveitis (inflammation of the uvea): 1 person, 25.00%
  2. Ulcerative Keratitis (ulcerative inflammation of the cornea): 1 person, 25.00%
  3. Scratch: 1 person, 25.00%
  4. Pyoderma Gangrenosum (ulcerating condition of skin that results in heaped borders with a typical appearance): 1 person, 25.00%
  5. Pupillary Disorder (disorder of the pupil of eyes): 1 person, 25.00%
  6. Keratitis Bacterial (inflammation of the cornea due to bacterial infection): 1 person, 25.00%
  7. Fall: 1 person, 25.00%
  8. Amaurosis (partial or total blindness without visible change in the eye): 1 person, 25.00%

Common conditions people have *:

  1. Diabetes: 1 person, 25.00%
  2. Ankylosing Spondylitis (type of arthritis affecting the spine): 1 person, 25.00%

* Approximation only. Some reports may have incomplete information.

Do you take Remicade and have Eye penetration?

Check whether Eye penetration is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

How severe was Eye penetration and when was it recovered:

Expand to all the drugs that have ingredients of infliximab:

Alternative drugs to, pros and cons of Remicade:

Common Remicade side effects:

Browse all side effects of Remicade:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Eye penetration treatments and more:

COVID vaccines that are related to Eye penetration:

All the drugs that are associated with Eye penetration:

All the conditions that are associated with Eye penetration:

How the study uses the data?

The study uses data from the FDA. It is based on infliximab (the active ingredients of Remicade) and Remicade (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).


WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: